CA2929499C — Composition of a non-nucleoside reverse transcriptase inhibitor
Assigned to Merck Sharp and Dohme LLC · Expires 2019-01-08 · 7y expired
What this patent protects
The invention encompasses a composition comprising the reverse transcriptase ("RT") inhibitor 3-chloro-5-({1-[(4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl}oxy)benzonitrile sufficiently mixed in a concentration…
USPTO Abstract
The invention encompasses a composition comprising the reverse transcriptase ("RT") inhibitor 3-chloro-5-({1-[(4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl}oxy)benzonitrile sufficiently mixed in a concentration enhancing polymer, and processes for making the same. The composition and processes of the present invention significantly improve the bioavailability of the aforementioned RT inhibitor, while maintaining physical stability.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.